Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000865554 | SCV001006542 | benign | Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 | 2023-12-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001011316 | SCV001171621 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-07 | criteria provided, single submitter | clinical testing | The p.R465Q variant (also known as c.1394G>A), located in coding exon 10 of the SDHA gene, results from a G to A substitution at nucleotide position 1394. The arginine at codon 465 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV001547986 | SCV001767824 | uncertain significance | not provided | 2024-02-22 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as a pathogenic or benign germline variant to our knowledge; This variant is associated with the following publications: (PMID: 30616628, 30680959, 26928227, 23849264, 37312221) |